Want to see CH:MMTX full AI Analyst Report?
Top Page
MindMaze Therapeutics Holding SA
(MMTX)
Select Model
Select Model
Rating:41Neutral
Price Target:
CHF1.00
▲(426.32% Upside)
Action:Reiterated
Date:01/24/26
The score is primarily held back by weak financial fundamentals (continued losses and negative free cash flow) and bearish technicals (below major moving averages with negative MACD). Valuation does not provide support because the company is unprofitable and no dividend yield is available.
Positive Factors
High gross margin
A gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.
Negative Factors
Persistent negative profitability
Ongoing net losses and negative operating margins indicate the core business is not yet self-sustaining. Over the medium term the company must either achieve sustained positive operating leverage or secure repeated external funding, otherwise cash burn will constrain R&D and commercialization plans.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin
A gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.
Read all positive factors
MindMaze Therapeutics Holding SA (MMTX) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF31.90M
Dividend YieldN/A
Average Volume (3M)1.39M
Price to Earnings (P/E)―
Beta (1Y)-0.67
Revenue GrowthN/A
EPS GrowthN/A
CountryCH
Employees10
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding181,497,670
10 Day Avg. Volume1,803,034
30 Day Avg. Volume1,390,979
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MindMaze Therapeutics Holding SA Business Overview & Revenue Model
Company Description
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic n...
How the Company Makes Money
RELIEF THERAPEUTICS generates revenue through multiple channels, including the development and licensing of its drug candidates to pharmaceutical companies, which may involve milestone payments and royalties on sales. The company may also engage i...
MindMaze Therapeutics Holding SA Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
MindMaze Therapeutics Holding SA Technical Analysis
Neutral
0.19
Price Trends
0.20
Negative
0.27
Negative
0.89
Negative
Market Momentum
>-0.01
Positive
47.93
Neutral
29.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MMTX, the sentiment is Neutral. The current price of 0.19 is below the 20-day moving average (MA) of 0.21, below the 50-day MA of 0.20, and below the 200-day MA of 0.89, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.93 is Neutral, neither overbought nor oversold. The STOCH value of 29.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:MMTX.
MindMaze Therapeutics Holding SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | CHF777.79M | 15.42 | ― | ― | 4.74% | -28.96% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | CHF138.08M | -2.49 | -67.67% | ― | -100.00% | 24.46% | |
49 Neutral | CHF253.41M | -19.36 | 277.88% | ― | -63.05% | -187.61% | |
48 Neutral | CHF221.63M | -4.05 | 684.83% | ― | 97.32% | -11.07% | |
45 Neutral | CHF1.34B | -3.97 | ― | ― | -8.06% | -87.00% | |
41 Neutral | CHF31.90M | -2.13 | -49.18% | ― | ― | ― |
* General Sector Average
CH:MMTX
MindMaze Therapeutics Holding SA
0.17
-2.67
-93.91%
CH:MOLN
Molecular Partners AG
3.39
0.49
16.90%
CH:BSLN
Basilea Pharmaceutica
65.70
19.35
41.75%
CH:IDIA
Idorsia Ltd
5.20
2.48
90.99%
CH:NWRN
Newron Pharmaceuticals SpA
12.28
4.05
49.21%
CH:SANN
Santhera Pharmaceuticals Holding
15.48
1.78
12.99%
MindMaze Therapeutics Holding SA Corporate Events
MindMaze Sets Global Reimbursement Framework to Scale AI-Powered Neurorehabilitation
Dec 23, 2025
MindMaze Therapeutics has detailed a coordinated global reimbursement strategy designed to scale access to its next-generation digital neurorehabilitation therapies and underpin long-term commercial growth. Central to the plan is a U.S. CMS Catego...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.